This site is intended for Healthcare professionals only.
×

Shanghai Junshi Biosciences soars 21 percent on Hong Kong debut


Shanghai Junshi Biosciences soars 21 percent on Hong Kong debut

Shanghai-based Junshi Biosciences has a pipeline of 13 biologic drug candidates, including immuno-oncology drugs and drugs targeting metabolic and inflammation or autoimmune diseases, its listing prospectus showed.

HONG KONG: Chinese biotech startup Shanghai Junshi Biosciences Co Ltd soared more than 21 per cent in its Hong Kong debut on Monday after raising $394 million in its IPO, a rare strong showing by a biotech company in the financial hub.

Shares opened at HK$23.50 ($3.00), 21.3 per cent higher than the initial public offering price (IPO) of HK$19.38.

That makes its performance the best so far among biotech companies that have listed in Hong Kong, which earlier this year changed its rules to allow listings from pre-revenue biotechs.

Innovent Biologics’s stock leapt almost 20 per cent on its listing in October, boosting hopes for the sector after the first few companies plunged below their IPO prices.

Hong Kong has enjoyed its best year since 2010 in terms of listings, with companies raising $36.3 billion, more than anywhere else in the world.

But performance has been poor, with many of the big-ticket listings tradings below their IPO prices.

Shanghai-based Junshi Biosciences has a pipeline of 13 biologic drug candidates, including immuno-oncology drugs and drugs targeting metabolic and inflammation or autoimmune diseases, its listing prospectus showed.

Its JS001 or toripalimab, which treats patients with unresectable or metastatic melanoma who have failed previous systemic therapies, won China’s first approval for a home-grown PD-1 monoclonal antibody.

CICC was the sole sponsor for the float. Along with Citi and Credit Suisse, the Chinese bank is also among joint bookrunners.

Also Read: Junshi Biosciences raises $394 million after pricing IPO at bottom of range

The following two tabs change content below.
MD Team

MD Team

At Medical Dialogues, we are a team of young professionals strongly advocating of the transparency in the medical sector through the free flow of medical information, health and medical news. MD Team covers a variety of news related to the healthcare, pharma and medical device industry in India. Our team can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: REUTERS
0 comment(s) on Shanghai Junshi Biosciences soars 21 percent on Hong Kong debut

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted